APPROACH: RNA-sequence target identification
STRATEGIC AREA: ASO (Anti-sense Oligonucleotide) therapeutics for bleeding disorder
P2C FUNDING IMPACT: Factor XI deficiency and women with Hemophilia
DATE OF INVESTMENT: September 2023
APPROACH: Non-invasive vagus nerve stimulation
STRATEGIC AREA: Non-invasive medical device
P2C FUNDING IMPACT: Von Willebrand Disease and women with Heavy Menstrual Bleeding
DATE OF INVESTMENT: October 2023